Expression and distribution of vasoactive intestinal polypeptide receptor VPAC2 mRNA in human airways

Laboratory Investigation

Volumn 81, Issue 5, 2001, Pages 749-755

  Groneberg, David A ^a,b   Hartmann, Petra ^b   Dinh, Q Thai ^a   Fischer, Axel ^a,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RECEPTOR SUBTYPE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

AIRWAY; ARTICLE; BINDING SITE; BRONCHUS; CONTROLLED STUDY; CYTOCHEMISTRY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MUSCLE CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRACHEA;

EID: 0034998194     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780283     Document Type: Article

References (44)

1. Adamou JE, Aiyar N, Van Horn S, and Elshourbagy NA (1995). Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. Biochem Biophys Res Commun 209:385-392.
2. Altiere RJ and Diamond L (1984). Comparison of vasoactive intestinal peptide and isoproterenol relaxant effects in isolated cat airways. J Appl Physiol 56:986-992.
3. Barnes PJ, Cadieux A, Carstairs JR, Greenberg B, Polak JM, and Rhoden K (1986). Vasoactive intestinal peptide in bovine pulmonary artery: Localisation, function and receptor autoradiography. Br J Pharmacol 89:157-162.
4. Bellinger DL, Lorton D, Brouxhon S, Felten S, and Felten DL (1996). The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol 6:5-27.
5. Busto R, Prieto JC, Bodega G, Zapatero J, and Carrero I (2000). Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides 21:265-269.
6. Carstairs JR and Barnes PJ (1986). Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung. J Pharmacol Exp Ther 239:249-255.
7. Ciccarelli E, Vilardaga JP, De Neef P, Di Paolo E, Waelbroeck M, Bollen A, and Robberecht P (1994). Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regul Pept 54:397-407.
8. Dey RD, Shannon WA Jr, and Said SI (1981). Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res 220:231-238.
9. Elgavish A, Pillion DJ, and Meezan E (1989). Evidence for vasoactive intestinal peptide receptors in apical membranes from tracheal epithelium. Life Sci 44:1037-1042.
10. Fischer A, Kummer W, Couraud JY, Adler D, Branscheid D, and Heym C (1992). Immunohistochemical localization of receptors for vasoactive intestinal peptide and substance P in human trachea. Lab Invest 67:387-393.
11. Frandsen EK, Krishna GA, and Said SI (1978). Vasoactive intestinal polypeptide promotes cyclic adenosine 3′,5′-monophosphate accumulation in guinea-pig trachea. Br J Pharmacol 62:367-369.
12. Ghatei MA, Sheppard MN, O'Shaughnessy DJ, Adrian TE, McGregor GP, Polak JM, and Bloom SR (1982). Regulatory peptides in the mammalian respiratory tract. Endocrinology 111:1248-1254.
13. Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Waelbroeck M, and Robberecht P (1997). The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides 18:403-408.
14. Greenberg B, Rhoden K, and Barnes PJ (1987). Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries. Blood Vessels 24:45-50.
15. Hamasaki Y, Mojarad M, and Said SI (1983a). Relaxant action of VIP on cat pulmonary artery: Comparison with acetylcholine, isoproterenol, and PGE1. J Appl Physiol 54:1607-1611.
16. Hamasaki Y, Saga T, Mojarad M, and Said SI (1983b). Vasoactive intestinal peptide counteracts leukotriene D4-induced contractions of guinea pig trachea, lung, and pulmonary artery. Trans Assoc Am Physicians 96:406-411.
17. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, and Waschek JA (1998). International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265-270.
18. Ichikawa S, Sreedharan SP, Owen RL, and Goetzl EJ (1995). Immunochemical localization of type I VIP receptor and NK-1-type substance P receptor in rat lung. Am J Physiol 268:L584-588.
19. Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, Gonoi T, Miyazaki J, and Seino S (1994). Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci USA 91:2679-2683.
20. Ishihara T, Shigemoto R, Mori K, Takahashi K, and Nagata S (1992). Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811-819.
21. Kaltreider HB, Ichikawa S, Byrd PK, Ingram DA, Kishiyama JL, Sreedharan SP, Warnock ML, Beck JM, and Goetzl EJ (1997). Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am J Respir Cell Mol Biol 16:133-144.
22. Laitinen A, Partanen M, Hervonen A, Pelto-Huikko M, and Laitinen LA (1985). VIP like immunoreactive nerves in human respiratory tract. Light and electron microscopic study. Histochemistry 82:313-319.
23. Laitinen LA, Laitinen A, Salonen RO, and Widdicombe JG (1987). Vascular actions of airway neuropeptides. Am Rev Respir Dis 136:S59-64.
24. Lazarus SC, Basbaum CB, Barnes PJ, and Gold WM (1986). cAMP immunocytochemistry provides evidence for functional VIP receptors in trachea. Am J Physiol 251:C115-119.
25. Lundberg JM, Anggard A, Emson P, Fahrenkrug J, and Hokfelt T (1981). Vasoactive intestinal polypeptide and cholinergic mechanisms in cat nasal mucosa: Studies on choline acetyltransferase and release of vasoactive intestinal polypeptide. Proc Natl Acad Sci USA 78:5255-5259.
26. Lundberg JM, Fahrenkrug J, Hokfelt T, Mantling CR, Larsson O, Tatemoto K, and Anggard A (1984). Co-existence of peptide HI (PHI) and VIP in nerves regulating blood flow and bronchial smooth muscle tone in various mammals including man. Peptides 5:593-606.
27. Lung MA and Widdicombe JG (1987). Lung reflexes and nasal vascular resistance in the anaesthetized dog. J Physiol 386:465-474.
28. Luts A and Sundler F (1989). Peptide-containing nerve fibers in the respiratory tract of the ferret. Cell Tissue Res 258:259-267.
29. Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, and Harmar AJ (1993). The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334:3-8.
30. Maggi CA, Giachetti A, Dey RD, and Said SI (1995). Neuropeptides as regulators of airway function: Vasoactive intestinal peptide and the tachykinins. Physiol Rev 75:277-322.
31. Malm L, Sundler F, and Uddman R (1980). Effects of vasoactive intestinal polypeptide on resistance and capacitance vessels in the nasal mucosa. Acta Otolaryngol 90:304-308.
32. Matran R, Alving K, Martling CR, Lacroix JS, and Lundberg JM (1989a). Effects of neuropeptides and capsaicin on tracheobronchial blood flow of the pig. Acta Physiol Scand 135:335-342.
33. Matran R, Alving K, Martling CR, Lacroix JS, and Lundberg JM (1989b). Vagally mediated vasodilation by motor and sensory nerves in the tracheal and bronchial circulation of the pig. Acta Physiol Scand 135:29-37.
34. Nandiwada PA, Kadowitz PJ, Said SI, Mojarad M, and Hyman AL (1985). Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat. J Appl Physiol 58:1723-1728.
35. Obara H, Kusunoki M, Mori M, Mikawa K, and Iwai S (1989). The effects of various peptides on the isolated pulmonary artery. Peptides 10:241-243.
36. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Simko B, Renzetti L, Tannu SA, Wasserman MA, Welton A, and Bolin DR (1994a). Ro 25-1553: A novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther 270:1282-1288.
37. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Tocker JE, Tannu SA, Wasserman MA, Welton A, and Bolin DR (1994b). Ro 25-1553: A novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis. J Pharmacol Exp Ther 270:1289-1294.
38. Rawlings SR, Piuz I, Schlegel W, Bockaert J, and Journot L (1995). Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs. Endocrinology 136:2088-2098.
39. Robberecht P, Chatelain P, de Neef P, Camus JC, Waelbroeck M, and Christophe J (1981). Presence of vasoactive intestinal peptide receptors coupled to adenylate cyclase in rat lung membranes. Biochim Biophys Acta 678:76-82.
40. Robberecht P, Waelbroeck M, de Neef P, Camus JC, Coy DH, and Christophe J (1988). Pharmacological characterization of VIP receptors in human lung membranes. Peptides 9:339-345.
41. Svoboda M, Tastenoy M, Van Rampelbergh J, Goossens JF, de Neef P, Waelbroeck M, and Robberecht P (1994). Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 205:1617-1624.
42. Usdin TB, Bonner TI, and Mezey E (1994). Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662-2680.
43. Wei Y and Mojsov S (1996). Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: Implications for their role in human physiology. J Neuroendocrinol 8:811-817.
44. Xia M, Sreedharan SP, Bolin DR, Gaufo GO, and Goetzl EJ (1997). Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther 281:629-633.